NuVasive to Participate in Upcoming Investor Conferences

Rhea-AI Summary

NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, announced participation in three upcoming investor conferences. The events are the Citi 2023 Healthcare Services Conference on March 2 in New York City, Cowen's 43rd Annual Health Care Conference on March 8 in Boston, and Barclays Global Healthcare Conference on March 14 in Miami. Management will discuss the recent merger with Globus Medical. Live webcasts of the presentations will be available on the company's Investor Relations page, with replays accessible for 30 days. NuVasive aims to transform surgery with minimally invasive solutions, generating over $1 billion in net sales across 50 countries.

SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies' recent merger announcement and other business topics:

• Citi 2023 Healthcare Services, MedTech, Tools and HCIT Conference, March 2, 2023 in New York City. The fireside chat will begin at 9:30 a.m. ET.
• Cowen's 43^rd Annual Health Care Conference, March 8, 2023 in Boston. The fireside chat will begin at 2:10 p.m. ET.
• Barclays Global Healthcare Conference, March 14, 2023 in Miami. The fireside chat will begin at 10:45 a.m. ET.

Live webcasts of the presentations will be available on the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcasts, replays of the presentations will remain available on the website for 30 days. 

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.

Globus Medical and NuVasive Announcement
On February 9, 2023, Globus Medical and NuVasive announced a definitive agreement to combine the companies in an all-stock transaction. The announcement can be found on the Investor Relations section of our website.

No Offer or Solicitation
This news release is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. 

Important Information About the Transaction and Where To Find It
In connection with the proposed transaction, Globus Medical will file with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 that will include a joint proxy statement of Globus Medical and NuVasive and that will also constitute a prospectus of Globus Medical for shares of its class A common stock to be offered in the proposed transaction. Globus Medical and NuVasive may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the joint proxy statement statement/prospectus or registration statement or any other document which Globus Medical or NuVasive may file with the SEC. INVESTORS AND SECURITY HOLDERS OF GLOBUS MEDICAL AND NUVASIVE ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH WILL INCLUDE THE JOINT PROXY STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement, definitive joint proxy statement/prospectus and other documents filed by Globus Medical and NuVasive with the SEC will be available free of charge at the SEC's website (www.sec.gov) and from Globus Medical and NuVasive. Requests for copies of the joint proxy statement/ prospectus and other documents filed by Globus Medical with the SEC may be made by contacting Keith Pfeil, Chief Financial Officer by phone at (610) 930-1800 or by email at kpfeil@globusmedical.com, and request for copies of the joint proxy statement/prospectus and other documents filed by NuVasive may be made by contacting Matt Harbaugh, Chief Financial Officer, by phone at (858) 210-2129 or by email at investorrelations@nuvasive.com.

Participants in the Solicitation
Globus Medical, NuVasive, their respective directors and certain of their executive officers and other employees may be deemed to be participants in the solicitation of proxies from Globus Medical's and NuVasive's shareholders in connection with the proposed transaction. Information about the directors and executive officers of Globus Medical and their ownership of Globus Medical stock is set forth in Globus Medical's annual report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 21, 2023 and its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 21, 2022. Information regarding NuVasive's directors and executive officers is contained in NuVasive's annual report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023, and its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on March 30, 2022. Certain directors and executive officers of Globus Medical and NuVasive may have a direct or indirect interest in the transaction due to securities holdings, vesting of equity awards and rights to severance payments. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Globus Medical's and NuVasive's shareholders in connection with the proposed transaction will be included in the joint proxy statement/prospectus. These documents can be obtained free of charge from the sources indicated above.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-to-participate-in-upcoming-investor-conferences-301757078.html

SOURCE NuVasive, Inc.

FAQ

What conferences is NuVasive participating in March 2023?

NuVasive will participate in the Citi 2023 Healthcare Services Conference on March 2, Cowen's 43rd Annual Health Care Conference on March 8, and the Barclays Global Healthcare Conference on March 14, 2023.

What is the significance of the merger between NuVasive and Globus Medical?

The merger aims to enhance spine surgery technology and expand market reach, benefiting both companies and their stakeholders.

When will NuVasive's conference presentations be available online?

Live webcasts of the presentations will be available on the Investor Relations page, with replays accessible for 30 days after each event.

How much revenue does NuVasive generate?

NuVasive generates over $1 billion in net sales, serving over 50 countries in the spine technology sector.

What time will the NuVasive presentations take place?

The presentations will take place at 9:30 a.m. ET on March 2, 2:10 p.m. ET on March 8, and 10:45 a.m. ET on March 14, 2023.